PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million

Reuters

Mar 28

PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million

PAVmed published its annual report on Form 10-K for FY 2025.
Revenue fell 96.67% to USD 0.1 million, reflecting the deconsolidation of Lucid from the company’s operating results after Sept. 10, 2024.
General and administrative expenses decreased 33.47% to USD 16.3 million.
Research and development expenses declined 23.73% to USD 4.5 million, also primarily due to Lucid no longer being included in results.
The company reported a net loss before noncontrolling interests of USD 2.5 million.
PAVmed ended FY 2025 with cash on hand of USD 1.5 million.
Management said substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
Management cited reliance on cost controls, higher Veris platform revenue, and additional financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-010115), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622034098"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622034098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622034098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622034098","market":"nz","top_or_hot":-1,"title":"PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          PAVmed published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for FY 2025.\n        </li>\n<li>\n          Revenue fell 96.67% to USD 0.1 million, reflecting the deconsolidation of <a href=\"https://laohu8.com/S/LCID\">Lucid</a> from the company’s operating results after Sept. 10, 2024.\n        </li>\n<li>\n          General and administrative expenses decreased 33.47% to USD 16.3 million.\n        </li>\n<li>\n          Research and development expenses declined 23.73% to USD 4.5 million, also primarily due to Lucid no longer being included in results.\n        </li>\n<li>\n          The company reported a net loss before noncontrolling interests of USD 2.5 million.\n        </li>\n<li>\n          PAVmed ended FY 2025 with cash on hand of USD 1.5 million.\n        </li>\n<li>\n          Management said substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.\n        </li>\n<li>\n          Management cited reliance on cost controls, higher Veris platform revenue, and additional financing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-010115), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 05:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          PAVmed published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for FY 2025.\n        </li>\n<li>\n          Revenue fell 96.67% to USD 0.1 million, reflecting the deconsolidation of <a href=\"https://laohu8.com/S/LCID\">Lucid</a> from the company’s operating results after Sept. 10, 2024.\n        </li>\n<li>\n          General and administrative expenses decreased 33.47% to USD 16.3 million.\n        </li>\n<li>\n          Research and development expenses declined 23.73% to USD 4.5 million, also primarily due to Lucid no longer being included in results.\n        </li>\n<li>\n          The company reported a net loss before noncontrolling interests of USD 2.5 million.\n        </li>\n<li>\n          PAVmed ended FY 2025 with cash on hand of USD 1.5 million.\n        </li>\n<li>\n          Management said substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.\n        </li>\n<li>\n          Management cited reliance on cost controls, higher Veris platform revenue, and additional financing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-010115), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PAVM","symbol_name":"PAVmed Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8B5X3w:1","article_id":"2622034098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622034098","pubTimestamp":1774645748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PAVmed published its annual report on Form 10-K for FY 2025.Revenue fell 96.67% to USD 0.1 million, reflecting the deconsolidation of Lucid from the company’s operating results after Sept. 10, 2024.General and administrative expenses decreased 33.47% to USD 16.3 million.Research and development expenses declined 23.73% to USD 4.5 million, also primarily due to Lucid no longer being included in results.The company reported a net loss before noncontrolling interests of USD 2.5 million.PAVmed ended FY 2025 with cash on hand of USD 1.5 million.Management cited reliance on cost controls, higher Veris platform revenue, and additional financing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PAVM":"PAVmed Inc.","BK4082":"医疗保健设备"},"translate_title":"PAVmed 2025财年收入下降96.67%至10万美元；运营现金流出收窄40%至520万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAVM":0.9},"content_text":"PAVmed FY2025 revenue drops 96.67% to $0.1 million; operating cash outflow narrows 40% to $5.2 million\n    \n\n\n          PAVmed published its annual report on Form 10-K for FY 2025.\n        \n\n          Revenue fell 96.67% to USD 0.1 million, reflecting the deconsolidation of Lucid from the company’s operating results after Sept. 10, 2024.\n        \n\n          General and administrative expenses decreased 33.47% to USD 16.3 million.\n        \n\n          Research and development expenses declined 23.73% to USD 4.5 million, also primarily due to Lucid no longer being included in results.\n        \n\n          The company reported a net loss before noncontrolling interests of USD 2.5 million.\n        \n\n          PAVmed ended FY 2025 with cash on hand of USD 1.5 million.\n        \n\n          Management said substantial doubt exists about the company’s ability to continue as a going concern within one year after issuance of the financial statements.\n        \n\n          Management cited reliance on cost controls, higher Veris platform revenue, and additional financing.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-010115), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}